Laventair Ellipta (Umeclidinium Bromide, Vilanterol)

Laventair Ellipta is indicated for maintenance bronchodilation in chronic airway diseases.

• Chronic obstructive pulmonary disease (COPD): improves lung function, reduces exacerbation frequency, and enhances exercise tolerance.
• Asthma (maintenance therapy): provides long‑term bronchodilation and helps achieve better symptom control.
• Chronic bronchitis (as part of COPD): maintains airway patency and reduces cough severity.

• Umeclidinium bromide selectively blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. Vilanterol activates β2‑adrenergic receptors, stimulating adenylate cyclase, increasing intracellular cAMP, and causing relaxation of bronchial smooth muscle. The combined LAMA/LABA action produces sustained bronchodilation and improves airflow in the lower respiratory tract.

Common Side Effects

• Cough or throat irritation: mild irritation after inhalation.
• Headache: transient, often resolves without intervention.
• Dry mouth: reduced salivation due to anticholinergic activity.
• Nasopharyngitis: upper respiratory tract infection symptoms.
• Upper respiratory tract infection: mild viral‑like symptoms.

Serious or Rare Side Effects

• Paradoxical bronchospasm: sudden worsening of breathing requiring immediate medical attention.
• Tachycardia or arrhythmia: rapid or irregular heart rhythm.
• Severe hypersensitivity reactions: rash, swelling, or anaphylaxis.
• Angioedema: swelling of lips, tongue, or throat.
• Cardiovascular events: chest pain or myocardial ischemia in susceptible patients.

Before prescribing Laventair Ellipta, consider the following precautions:

• Cardiovascular assessment: evaluate patients with known heart disease for potential tachycardia.
• COPD severity monitoring: watch for worsening symptoms or frequent exacerbations.
• History of paradoxical bronchospasm: avoid use if previously experienced.
• Hepatic impairment: use with caution in severe liver disease.
• Known hypersensitivity: do not administer to patients allergic to either component.
• Store at room temperature: keep in original blister, protect from moisture and heat.

Laventair Ellipta may interact with other medicines. Review patient medication lists carefully.

Major Interactions (Avoid)

• Beta‑blockers: may diminish bronchodilator effect and increase risk of bronchospasm.
• Other long‑acting muscarinic antagonists: additive anticholinergic effects can lead to dry mouth, urinary retention, or glaucoma.

Moderate Interactions (Monitor Closely)

• Diuretics: may exacerbate dry mouth and dehydration.
• Theophylline: vilanterol can increase plasma theophylline levels, requiring dose adjustment.
• Anticholinergic eye drops: may increase systemic anticholinergic load, leading to blurred vision or urinary retention.